Wednesday's Small-Cap Winners & Losers
Small-cap stocks hovered above the broader market Wednesday for most of the day as upbeat news surfaced from a variety of sectors.
Cypress Bioscience (CYPB) was still riding high after surging late Tuesday on positive preliminary results from a late-stage trial of milnacipran for treatment of fibromyalgia syndrome. Shares nearly doubled at $16.37 after a CIBC World Markets analyst upped the stock to outperform. Forest Laboratories (FRX), which jointly announced these results with Cypress, lately added 2.2% to $53.
Semiconductor Advanced Analogic Technologies (AATI) also garnered an upgrade -- to buy from hold, at Needham & Co. -- after Tuesday's after-hours announcement of a favorable "initial determination" ruling from a patent-infringement case brought by Linear Technology (LLTC). After an extended-trading leap, AnalogicTech shares still climbed 16.5% higher to $9.33. Linear slid 3.6% to $35.79.
Cypress and Analogic both supported the Russell 2000, which enjoyed a few hours on the upswing before careening down to flat-line along with the rest of the market. The index was off 0.4% at 836.54.Also among small-cap gainers today was Mesa Laboratories (MLAB). Shares vaulted 22.6% to $22.68 after the Colorado-based medical-equipment maker reported fiscal fourth-quarter earnings of $1.4 million, or 44 cents a share, compared with 27 cents a share a year ago. Sales soared 53.6% to $5.3 million. SenoRx (SENO), based in California, said the Food and Drug Administration cleared for commercialization its Multi-Lumen Radiation Balloon Applicator for brachytherapy in breast cancer patients. (Brachytherapy involves implanting small radioactive "seeds" that kill cancer cells.) Shares jumped 13.5%, or $1.08, to $9.08.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV